Related Experiment Video
Updated: Jun 23, 2026
10:14
Recapitulation of an Ion Channel IV Curve Using Frequency Components
Published on: February 8, 2011
The interactions between hERG potassium channel and blockers.
Lupei Du1, Minyong Li, Qidong You
1Department of Medicinal Chemistry and Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing 210009, China.
Current Topics in Medicinal Chemistry
|May 16, 2009
Summary
Understanding how drugs interact with the human ether-a-go-go related gene (hERG) potassium channel is crucial for preventing dangerous heart arrhythmias. Computational modeling aids in predicting drug safety and designing safer medications.
Area of Science:
- Cardiovascular Pharmacology
- Molecular Biology
- Computational Chemistry
Background:
- The human ether-a-go-go related gene (hERG) potassium channel regulates the heart's QT interval.
- hERG channel blockade can cause fatal Torsades de Pointes (TdP) arrhythmia.
- Limited understanding of ligand-hERG interactions hinders the development of safe drugs.
Purpose of the Study:
- To review in silico studies on ligand-hERG interactions.
- To elucidate the molecular basis of hERG channel blockade.
- To improve prediction of QT prolongation liability for drug development.
Main Methods:
- In silico receptor-based modeling.
- In silico ligand-based modeling.
- Review of recent studies on ligand-hERG interactions.
Main Results:
- Computational approaches provide insights into ligand binding determinants.
- Modeling aids in understanding the molecular mechanisms of hERG blockade.
- These methods facilitate rational drug design for improved safety.
Conclusions:
- In silico modeling is valuable for understanding hERG channel interactions.
- This approach supports the development of safer non-cardiac drugs.
- Predicting and mitigating QT prolongation risk is enhanced by these computational tools.
Related Concept Videos
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:28Depolarizing Blockers: Mechanism of Action
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:19Depolarizing Blockers: Pharmocokinetics
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...